Development of tissue-targeting hemagglutinating virus of Japan envelope vector for successful delivery of therapeutic gene to mouse skin.
We report a novel strategy for constructing a tissue-targeting hemagglutinating virus of Japan (HVJ; Sendai virus) envelope vector (HVJ-E), and its application in gene therapy of a mouse model of genetic skin disease. Chimeric genes encoding viral F protein and green fluorescent protein (GFP) were constructed on the basis of various deletion mutants. The product of one chimeric gene, containing signal peptide, transmembrane domain, and the cytoplasmic tail of F protein, was transported to the cell surface and incorporated into new viruses released from HVJ-infected LLC-MK2 cells. For tissue targeting, in the preceding construct GFP was replaced with single-chain antibody (scFv) against mouse desmoglein 3 (mDsg3), a desmosomal cadherin found in basal layer keratinocytes of the skin. HVJ encoding scFv-F chimeric protein bound to mDsg3-coated plates much more efficiently than did wild-type HVJ. When chimeric HVJ was injected into a skin blister of a mouse model of epidermolysis bullosa, in which defective expression of type VII collagen results in a failure to secure epidermis to the underlying dermis, viral F protein expression was detected in most of the basal keratinocytes. Furthermore, chimeric HVJ-E introduced type VII collagen expression more efficiently compared with wild-type HVJ in basal keratinocytes of type VII collagen-deficient mouse skin, resulting in efficient amelioration of the genetic defect. Thus, a novel tissue-targeting HVJ-E could be used to successfully target epidermal keratinocytes both in vitro and in vivo.
Kawachi
Masako
M
Division of Gene Therapy Science, Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan.
Tamai
Katsuto
K
Saga
Kotaro
K
Yamazaki
Takehiko
T
Fujita
Hiroshi
H
Shimbo
Takashi
T
Kikuchi
Yasushi
Y
Nimura
Keisuke
K
Nishifuji
Koji
K
Amagai
Masayuki
M
Uitto
Jouni
J
Kaneda
Yasufumi
Y
D000818:Animals; D002460:Cell Line; D051184:Desmoglein 3 / Q000378:metabolism*; D004820:Epidermolysis Bullosa / Q000235:genetics / Q000628:therapy*; D018390:Gene Targeting; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors; D015603:Keratinocytes / Q000166:cytology / Q000378:metabolism*; D051379:Mice; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism; D029082:Sendai virus / Q000235:genetics*; D014760:Viral Fusion Proteins / Q000235:genetics / Q000378:metabolism*
D051184:Desmoglein 3; C495300:Dsg3 protein, mouse; D011993:Recombinant Fusion Proteins; D014760:Viral Fusion Proteins